Media
Interviews, commentary and educational content across urology publications.
AUA2026 Insights: The Next Frontier: Evaluating Next-Generation Intravesical Agents for NMIBC
Part of the AUA 2026 Insights series, reviewing the next generation of intravesical agents for non-muscle-invasive bladder cancer and how they are being evaluated.
NCCN Guidelines Adopt IBCG Risk Model for Intermediate-Risk NMIBC
Quoted as an IBCG member and Yale faculty, commenting on the clinical relevance of the newly adopted 5-factor risk model for bladder cancer management.
Limitations of Urine-Based Biomarkers for Replacing Cystoscopy in Hematuria
In conversation with Ashish Kamat, presenting International Bladder Cancer Group (IBCG) 2025 consensus work on urine biomarkers, early detection and haematuria evaluation.
Device-Assisted Therapies for Bladder Cancer: History, Mechanisms, and Clinical Trials
With Ashish Kamat, reviewing the history, mechanisms and clinical trials of device-assisted treatments for non-muscle-invasive bladder cancer, including chemohyperthermia and EMDA, and newer options such as TAR-200.
Long-Term Survival Outcomes in Patients with BCG Unresponsive Non-Muscle Invasive Bladder Cancer: Evaluating Bladder-Sparing Treatment
Filmed at AUA 2023: in conversation with Ashish Kamat on long-term survival after bladder-sparing treatment compared with early radical cystectomy for BCG-unresponsive non-muscle-invasive bladder cancer.
HIVEC-II Phase 2 Trial Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk NMIBC
With Ashish Kamat, presenting the results of HIVEC-II, a UK randomised trial comparing heated (chemohyperthermia) with room-temperature mitomycin C for intermediate-risk non-muscle-invasive bladder cancer.
Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group: Intermediate-risk Non-muscle-invasive Bladder Cancer
With Ashish Kamat, presenting highlights of the International Bladder Cancer Group’s updated consensus on defining and managing intermediate-risk non-muscle-invasive bladder cancer.
The Role of Guidelines in the Management of Intermediate-Risk NMIBC
A three-way interview with colleagues from MD Anderson and Moffitt Cancer Center on IBCG recommendations and globally applicable guidelines.
Bladder-Sparing Options for BCG-Unresponsive Bladder Cancer
With Ashish Kamat, working through a case of high-grade recurrence after BCG and the bladder-sparing options for a patient who does not wish to have a radical cystectomy.
SIU 2019: Debate - Urinary Markers Are Useful in Management of Bladder Cancer
Conference report from the Société Internationale d’Urologie (SIU) 2019 congress in Athens, where Dr Tan made the case for urinary biomarkers in bladder cancer detection and surveillance.
EAU 2019: Development and External Validation of the Hematuria Cancer Risk Score to Identify Patient at Risk of Harboring Cancer
Conference report from the European Association of Urology (EAU) 2019 congress in Barcelona, on the development and external validation of a risk score to help select which patients with haematuria need investigation.